MiCheck® testing for prostate cancer: quick, non-invasive, highly specific
MiCheck® is a blood test that uses our patented monoclonal antibody together with other biomarkers to determine if a patient has prostate cancer and, if so, whether the cancer is likely to be aggressive or not.
The MiCheck® test is designed to assist urologists in making the decision to recommend a patient has a biopsy or moves onto some form of active surveillance monitoring.
The problem in prostate cancer diagnosis
The PSA test is commonly used to detect prostate cancer however elevated PSA levels can be caused by factors other than prostate cancer. This results in six in ten men (www.urologicalcancercentre.com.au) needlessly being subjected to an unnecessary needle biopsy.
- Are traumatic, painful, and potentially lead to infection, which can make a man reluctant to see if they really need treatment for prostate cancer;
- Add to health care costs, because biopsies are expensive.
The estimated over-diagnosis using PSA for population screening in the USA (American Cancer Society) is 23-29% for Caucasian men and 35-44% for African-American men.
The MiCheck® Solution for prostate cancer diagnosis
The MiCheck® test will assist urologists in making the decision to biopsy by indicating whether the patient has prostate cancer and whether it is aggressive or non-aggressive. Being a simple blood test MiCheck® is less invasive than a prostate biopsy and also returns an answer to the physician on the patient’s cancer status within 48 hours. The test works by measuring protein biomarkers including a proprietary marker owned by Minomic called Glypican -1.
Why is MiCheck® the missing step in prostate cancer diagnosis?
- It’s more specific than a PSA test – so a urologist can tell if a biopsy is really needed.
- Patients and their physicians will have confidence about what to do next. Patients who should get treatment for prostate cancer will get it sooner, and men whose MiCheck® results are negative can be monitored every year or two.